IMPROVED METHODS FOR RECOMBINANT PEPTIDE PRODUCTION

Abstract: The present invention provides improved methods for the production of recombinant peptides from bacterial cells.

Description: IMPROVED METHODS FOR RECOMBINANT PEPTIDE PRODUCTION The present invention relates generally to improved methods for the production of recombinant peptides from bacterial cells. BACKGROUND OF THE INVENTION Although bioactive peptides can be produced chemically by a variety of synthesis strategies, recombinant production of peptides, including those in the 5- 50 amino acid size range, offers the potential for large scale production at reasonable cost. However, expression of very short polypeptide chains can sometimes be problematic in microbial systems, including in bacterial cells such as Escherichia coli. This is true even when the peptide sequence is expressed as part of a fusion protein. As part of a fusion protein, peptides may be directed to specific cellular compartments, i.e. cytoplasm, periplasm, or media, with the goal of achieving high expression yield and avoiding cellular degradative processes. Preparation of a peptide from a fusion protein in pure form requires that the peptide be released and recovered from the fusion protein by some mechanism and then obtained by isolation or purification. Methods for cleaving fusion proteins have been identified. Each method recognizes a chemical or enzymatic cleavage site that links the carrier protein to the desired protein or peptide [Forsberg et al., I. J. Protein Chem. 11, 201-211, (1992)]. Chemical cleavage reagents in general recognize single or paired amino acid residues which may occur at multiple sites along the primary sequence, and therefore may be of limited utility for release of large peptides or protein domains which contain multiple internal recognition sites. However, recognition sites for chemical cleavage can be useful at the junction of short peptides and carrier proteins. Chemical cleavage reagents include cyanogen bromide, which cleaves at methionine residues [Piers et al., Gene, 134, 1 , (1993)], N-chloro succinimide [Forsberg et al, Biofactors 2, 105-112, (1989)] or BNPS-skatole [Knott et al., Eur. J. Biochem. 174, 405-410, (1988); Dykes et al, Eur. J. Biochem. 174, 411- 416, (1988)] which cleaves at tryptophan residues, dilute acid which cleaves aspartyl-prolyl bonds [Gram et al., Bio/Technology 12, 1017-1023, (1994); Marcus, Int. J. Peptide Protein Res., 25, 542-546, (1985)], and hydroxylamine which cleaves asparagine-glycine bonds at pH 9.0 [Moks et al., Bio/Technology 5, 379-382, (1987)]. Of interest is U.S. Patent No. 5,851,802 which describes a series of recombinant peptide expression vectors that encode peptide sequences derived from bactericidal/permeability-increasing protein (BPI) linked via amino acid cleavage site sequences as fusions to carrier protein sequences. In some fusion protein constructs, an acid labile aspartyl-prolyl bond was positioned at the junction between the peptide and carrier protein sequences. BPI-derived peptides were released from the fusion proteins by dilute acid treatment of isolated inclusion bodies without prior solubilization of the inclusion bodies. The released peptides were soluble in the aqueous acidic environment. In addition, BPI- derived peptides were obtained from fusion proteins under conditions where the fusion proteins were secreted into the culture medium. Those secreted fusion proteins were then purified and treated with dilute acid to release the peptide. Of additional interest are the disclosures of the following references which relate to recombinant fusion proteins and peptides. Shen, Proc. Nat 'I. Acad. Sci. (USA), 281, 4627 (1984) describes bacterial expression as insoluble inclusion bodies of a fusion protein encoding pro-insulin and β-galactosidase; the inclusion bodies were first isolated and then solubilized with formic acid prior to cleavage with cyanogen bromide. Kempe etal, Gene, 39, 239 (1985) describes expression as insoluble inclusion bodies in E. coli of a fusion protein encoding multiple units of neuropeptide substance P and β-galactosidase; the inclusion bodies were first isolated and then solubilized with formic acid prior to cleavage with cyanogen bromide. Lennicket fl/., Gene, 61, 703 (1987) describes expression as insoluble inclusion bodies in E. coli of a fusion protein encoding multiple units (8) of α-human atrial natriuretic peptide; the inclusion bodies were first isolated and then solubilized with urea prior to endoproteinase cleavage. Dykes et al, Eur. J. Biochem., 174, 41 1 (1988) describes soluble intracellular expression in E coli of a fusion protein encoding α-human atrial natriuretic peptide and chloramphenicolacetyltransferase;the fusion protein was proteolytically cleaved or chemically cleaved with 2-(2-nitrophenylsulphenyl)-E-methyl-3'-bromoindolenine to release peptide. Ray etal, Bio/Technology, 11, 64 (1993) describes soluble intracellular expression in E. coli of a fusion protein encoding salmon calcitonin and glutathione- S-transferase; the fusion protein was cleaved with cyanogen bromide. Schellenbergeretα/., Int. J. Peptide Protein Res., 41, 326 (1993) describes expression as insoluble inclusion bodies of a fusion protein encoding a substance P peptide (1 la.a.) and β-galactosidase; the inclusion bodies were first isolated and then treated with chymotrypsin to cleave the fusion protein. Hancock et al, WO94/04688 (PCT/CA93/00342) and Piers et al. (Hancock), Gene, 134, 1 (1993) describe (a) expression as insoluble inclusion bodies in E. coli of a fusion protein encoding a defensin peptide designated human neutrophil peptide 1 (HNP- 1 ) or a hybrid cecropin/mellitin (CEME) peptide and glutathione- 5- transferase (GST); the inclusion bodies were first isolated and then: (i) extracted with 3% octyl-polyoxyethyleneprior to urea solubilization and prior to factor X a protease for HNP 1 -GST fusion protein or (ii) solubilized with formic acid prior to cyanogen bromide cleavage for CEME-GST fusion protein; (b) expression in the extracellular supernatant of S aureus of a fusion protein encoding CEME peptide and protein A; (c) proteolytic degradation of certain fusion proteins with some fusion protein purified; and (d) proteolytic degradation of other fusion proteins and inability to recover and purify the fusion protein. Lai et al. , U.S. Patent No. 5,206, 154 and Callaway, Lai et al. Antimicrob. Agents & Chemo., 37: 1614 ( 1993) describe expression as insoluble inclusion bodies of a fusion protein encoding a cecropin peptide and the protein encoded by the 5'-end of the L-ribulokinase gene; the inclusion bodies were first isolated and then solubilized with formic acid prior to cleavage with cyanogen bromide. Gramm et al, Bio/Technology, 12:1011 (1994) describes expression as insoluble inclusion bodies in E. coli of a fusion protein encoding a human parathyroid hormone peptide and a bacteriophage T4-encoded gp55 protein; the inclusion bodies were first isolated (6% wt/vol.) and then were treated with acid to hydrolyze the Asp-Pro cleavage site. Kuliopulos et al, J. Am. Chem. Soc, 116:4599 (1994) describes expression as insoluble inclusion bodies in E. coli of a fusion protein encoding multiple units of a yeast α-mating type peptide and a bacterial ketosteroid isomerase protein; the inclusion bodies were first isolated and then solubilized with guanidine prior to cyanogen bromide cleavage. Pilon et al., Biotechnol Prog., 13, 374-379 (1997) describe soluble intracellular expression in E. coli of a fusion protein encoding a peptide and ubiquitin; the fusion protein was cleaved with a ubiquitin specific protease, UCH-L3. Haughtet al., Biotechnol. Bioengineer., 57, 55-61 (1998) describe expression as insoluble inclusion bodies in E. coli of a fusion protein encoding an antimicrobial peptide designated P2 and bovine prochymosin; the inclusion bodies were first isolated and then solubilized with formic acid prior to cleavage with cyanogen bromide. The above-references indicate that production of small peptides from bacteria has been problematic for a variety of reasons. Proteolysis of some peptides has been particularly problematic, even where the peptide is made as a part of a larger fusion protein. Such fusion proteins comprising a carrier protein/peptide may not be expressed by bacterial host cells or may be expressed but cleaved by bacterial proteases. In particular, difficulties in expressing cationic antimicrobial peptides in bacteria have been described by Hancock et al. WO94/04688 (PCT/CA93/00342) referenced above, due in their view to the susceptibility of such polycationic peptides to bacterial protease degradation. The production of peptide for preclinical and clinical evaluation often requires multigram quantities [Kelley, Bio/Technology 14, 28-31 (1996)]. If production of recombinant peptides can be achieved at this large scale, such production can potentially be economical. However, downstream processing steps for the production of peptides and proteins from bacteria can often contribute a significant fraction of total production cost. Initial recovery of peptide from bacterial inclusion bodies of fusion proteins, for example, generally requires multiple distinct processing steps, including the following four steps: (1) cell disruption/lysis, (2) isolation of inclusion bodies from the disrupted/lysed cells, (3) solubilization of the isolated inclusion bodies in denaturant or detergent to obtain solubilized fusion protein, and (4) fusion protein cleavage and separation of peptide and carrier protein. It is desirable that aspects of the recombinant production process be improved and/or optimized in order to make large-scale production of peptides by recombinant means more economically viable. There continues to exist a need in the art for improved methods for recombinant production of peptides from bacterial cells, particularly for simpler methods that do not require a multiplicity of steps, including, for example, the step of isolation or purification of peptide fusion proteins or the step of isolation or purification of inclusion bodies comprising the fusion proteins in order to obtain the recombinant peptide. SUMMARY OF THE INVENTION The present invention provides improved methods for the production of recombinant peptides from bacterial cells. The improved methods preclude the need for the isolation and solubilization of inclusion bodies or the isolation and purification of peptide fusion proteins. The improved methods accomplish cell disruption/lysis and release of peptide from bacterial cells or bacterial cell cultures in a single step. Fusion proteins useful in methods of the invention comprise at least one peptide sequence, a carrier protein sequence, and at least one acid- sensitive amino acid cleavage site sequence located between the peptide sequence and the carrier protein sequence. The invention provides improved methods for the microbial production of peptides from such fusion proteins expressed intracellularly in bacterial cells. The recombinant peptides recovered according to the invention are released by acid cleavage at the acid-sensitive cleavage site(s) in the fusion protein. Recombinant peptides are thus efficiently and economically produced according to the invention. The invention thus provides an improved method for obtaining a peptide from bacterial cells after expression inside the cells of a fusion protein, wherein the fusion protein comprises the peptide, a carrier protein and an acid-cleavable site between the peptide and the carrier protein, with the improvement comprising treating the bacterial cells with acid under conditions sufficient in a single step to disrupt or lyse the cells and release the peptide from the fusion protein. An improved method may include the additional step of obtaining the released peptide separated from the disrupted or lysed cells. According to the invention, the released peptide may be separated from the disrupted or lysed cells by a separation device, such as a centrifugation device or a filtration device. The invention also provides an improved method for obtaining a peptide from bacterial cells after expression inside the cells of a fusion protein, wherein the fusion protein comprises the peptide, a carrier protein and an acid-cleavable site between the peptide and the carrier protein with the improvement comprising the following steps: (a) treating the bacterial cells with acid under conditions sufficient to disrupt or lyse the cells and release the peptide from the fusion protein; (b) separating soluble material from insoluble material after step (a); and (c) recovering the released peptide in the soluble material after step (b). According to the invention, the soluble material may be separated from the insoluble material by a separation device, such as a centrifugation device or a filtration device. Improved methods of the invention may be employed where the bacterial cells are in cell culture media for the acid treatment, or where the bacterial cells have been separated from cell culture media for the acid treatment, or where the bacterial cells are in cell culture media in a fermentation vessel for the acid treatment. According to methods of the invention, preferred acid-cleavable sites in the fusion protein include an Asp-Pro cleavage site. Preferably, the carrier protein is expressed as an insoluble protein inside the bacterial cells. Improved methods of the invention for recombinant microbial production of peptides from fusion proteins are based on the surprising discovery that bacterial cell disruption/lysis and peptide release may be accomplished simultaneously in a single step. According to the invention, no process step is required for the isolation from the cells of inclusion bodies and solubilization of such inclusion bodies prior to peptide release and recovery. Similarly, no process step is required for the purification of the fusion proteins expressed in large amounts intracellularly as soluble or insoluble proteins in bacterial host cells prior to peptide release and recovery. Remarkably, peptides efficiently produced as components of fusion proteins by the bacterial host cells are efficiently cleaved and released from the fusion proteins by a single step of cell disruption/lysis and peptide release. It is particularly surprising that peptides according to the invention effectively made in E coli are released in soluble form in this single step of cell disruption/lysis and peptide cleavage and are easily recovered from insoluble cell material. By way of example, recombinant BPI-derived peptides having one or more of the biological activities of BPI (e.g., LPS binding, LPS neutralization, heparin binding, heparin neutralization, antimicrobial activity) have been produced and recovered according to the methods of invention. Thus, the invention provides improved methods of bacterial cell production of functional recombinant peptides. DETAILED DESCRIPTION The present invention provides improved recombinant peptide production methods. Recombinant peptides encoded by and released from fusion proteins are recovered according to these improved methods. Fusion proteins useful in methods according to the invention comprise a peptide sequence, a carrier protein sequence and an acid-sensitive amino acid cleavage site sequence between the peptide and carrier protein sequences. Improved methods according to the invention accomplish cell disruption/lysis and release of peptide from the cells in a single step using bacterial cells or bacterial cell cultures (e.g., fermentation cultures). The methods preclude the need for disruption/lysis followed by isolation and solubilization of inclusion bodies of the fusion proteins from the bacterial cells prior to peptide release and recovery. Unexpectedly, single step treatment of bacterial cells or bacterial cell cultures under conditions of acid pH and temperature sufficient to cleave and release peptides simultaneous with cell disruption/lysis, allows the direct recovery of soluble peptide from insoluble cell lysis material. Fusion proteins containing BPI-derived peptides with antimicrobial activity were expressed intracellularly in large amounts without significant proteolysis, until acidification of the bacterial cells. A variety of BPI- derived peptides, including those comprising the sequences listed in Table 4 of U.S. Patent No. 5,851 ,802 incorporated by reference herein in its entirety, may be produced by recombinant methods according to the invention. An advantage provided by the present invention is the ability to produce peptides from fusion proteins more efficiently and economically from bacterial host cells. Additional advantages include the ability to recover and obtain homogeneous peptide in large amounts via improved methods that are particularly amenable to scale-up in large fermentation vessels. "BPI-derived peptide" or "BPI peptide" as used herein refers to a peptide derived from or based on bactericidal/permeability-increasingprotein (BPI), including peptides derived from Domain I (amino acids 17-45), Domain II (amino acids 65-99) and Domain III (amino acids 142-169) of BPI (SEQ ID NOS: 15 and 16), each peptide having an amino acid sequence that is the amino acid sequence of a BPI functional domain or a subsequence thereof and variants of the sequence or subsequence having at least one of the biological activities of BPI . The amino acid sequence of the entire human BPI protein and the nucleic acid sequence of DNA encoding the protein have been reported in Figure 1 of Gray et al., J Biol. Chem., 264, 9505 (1989), incorporated herein by reference. The Gray et al. DNA and amino acid sequences are set out in SEQ ID NOS: 15 and 16 hereto. An N-terminal BPI fragment of approximately 23 kD, referred to as rBPI 23 , [Gazzano-Santoro et al., Infect, lmmun. 60, 4754-4761 (1992)], an analog designated rBPI 2! or rBPI 2] Δcys (U.S. Patent No. 5,420,019, incorporated by reference herein) as well as recombinant holoprotein, also referred to as rBPI, have been produced having sequences set out in SEQ ID NOS : 15 and 16, except that valine at position 151 is specified by GTG rather than GTC and residue 185 is glutamic acid (specified by GAG) rather than lysine (specified by AAG). As used herein, a "biological activity of BPI" refers to LPS binding, LPS neutralization, heparin binding, heparin neutralization or antimicrobial activity (including anti-bacterial and anti-fungal activity). Such BPI- derived peptides having at least one of the activities of BPI may be useful as antimicrobial agents (including anti-bacterial and anti-fungal agents), as endotoxin binding and neutralizing agents, and as heparin binding and neutralizing agents including agents for neutralizing the anticoagulant effects of administered heparin, for treatment of chronic inflammatory disease states, and for inhibition of normal or pathological angiogenesis. "Cationic BPI peptide" refers to a BPI peptide with a pi > 7.0. As used herein a "transformed bacterial host cell refers to a bacterial cell that contains recombinant genetic material or a bacterial cell that contains genetic material required for expression of a recombinant product. The genetic material may be introduced by any method known in the art including transformation, transduction, electroporationand infection. As used herein, a "vector" or "vector construct" refers to plasmid DNA that contains recombinant genetic material which may encode a recombinant product(s) and may be capable of autonomous replication in bacteria. "Carrier protein" as used herein refers to a protein that can be expressed in bacteria and used as a fusion partner to a linked peptide or protein. Preferred carrier proteins are those that can be expressed at high yield and when used as a fusion partner can confer high level-expression to a linked peptide or protein. Particularly preferred carrier proteins are those that are expressed intracellularly as soluble or insoluble proteins, such as the D subunit of a human osteogenic protein ("Bone D"). Any known carrier protein may be utilized as a protein fusion partner, including, for example, ubiquitin, [see e.g., Pilon et al., Biotechol. Prog. 13, 374-379 (1997)]; staphylococcal protein A, [see e.g., Uhlen et al., Gene 23, 369:378 (1983) and Piers et al., Gene 134, 7-13 (1993)]; thioredoxin, [see e.g., LaVallie et al., Bio/Technology 11, 187-193 (1993)]; maltose binding protein, [see e.g., Tsao et al., Gene 169, 59-64 (1996)]; glutathione-s-transferase,[see e.g., Ray et al., Bio/Technoloty 11 64-70 (1993) and Piers et al., Gene 134, 7-13 (1993)]; prochymosin, [see e.g., Haught et al., Biotechnology and Bioengineering 57, 55-61 (1998)]; β-galactosidase, [see e.g., Kempe et al., Gene 39, 239-245 (1985)]; and gp 55 from T4, [see e.g., Gram et al., Bio/Technology 12, 1017-1023 (1994)]. A "cationic carrier protein" as used herein refers to a carrier protein having a pi (as calculated based on amino acid sequence or as measured in solution) greater than 7.0 and preferably greater than 8.0. Such proteins include (1) Bone D (pi 8.18) (SEQ ID NOS: 1 and 2) and (2) gelonin (pi 9.58) (see, e.g., U.S. Patent Nos. 5,416,202 and 5,851,802, hereby incorporated by reference in their entirety). "Amino acid cleavage site" as used herein refers to an amino acid or amino acids that serve as a recognition site for a chemical or enzymatic reaction such that the peptide chain is cleaved at that site by the chemical agent or enzyme. Amino acid cleavage sites include those at aspartic acid - proline (Asp-Pro), methionine (Met), tryptophan (Tip) or glutamic acid (Glu). "Acid-sensitive amino acid cleavage site" as used herein refers to an amino acid or amino acids that serve as a recognition site such that the peptide chain is cleaved at that site by acid. Particularly preferred is the Asp-Pro cleavage site which may be cleaved between Asp and Pro by acid hydrolysis. Peptides derived from or based on BPI (BPI-derived peptides), are described in co-owned U.S. Patent No. 5,858,974 [WO 97/04008 (PCT/US96/03845)]; U.S. Patent Application Serial Nos. 08/504,841 and 09/1 19,858 [WO 96/08509 (PCT/US95/09262)]; U.S. Patent Nos. 5,652,332 and 5,856,438 [WO 95/19372 (PCT/US94/10427)]; U.S. Patent Nos. 5,733,872 and 5,763,567 [WO 94/20532 (PCT/US94/02465)]; U.S. Patent Nos. 4,348,942; 5,639,727; 5,807,818; 5,837,678; and 5,854.214 [WO 94/20128 (PCT/US94/ 02401)]; the disclosures of all of which are incorporated herein by reference. Other aspects and advantages of the present invention will be understood upon consideration of the following illustrative examples wherein Example 1 addresses construction of fusion protein expression vector constructs; Example 2 addresses expression of recombinant fusion proteins; Example 3 addresses acid hydrolysis of bacterial cells or bacterial cell cultures and release of recombinant peptide; Example 4 addresses acid hydrolysis of bacterial cell cultures in fermentation vessels; Example 5 addresses acid hydrolysis of bacterial cells after removal of cell culture medium; Example 6 addresses recovery and purification of recombinant peptides from acid hydrolyzed bacterial cells; and Example 7 addresses biological activity assays of recombinant peptides. EXAMPLE 1 Construction of Fusion Protein Expression Vectors 1. Bacterial Expression Vector Construct pING4702 A bacterial expression vector which would encode a peptide fusion protein, was constructed. This vector contains a sequence for a gene encoding subunit D of a human osteogenic protein ("Bone D") (see, amino acids 23 through 161 of SEQ ID NOS: 1 and 2), linked to a sequence encoding a linking sequence that includes the dipeptide Asp-Pro and a sequence encoding a peptide derived from the sequence of BPI (SEQ ID NO: 3). This vector construct, pING4702, was prepared in several steps as described below. First, two synthetic ohgonucleotides were synthesized that encode a BPI- derived peptide, an Asp-Pro dipeptide and appropriate restriction enzyme recognition sites for cloning. The ohgonucleotides encoding this sequence were: 5'-GATCCACCGAAAGTGGGTTGGCTGATCCAGCTGTTCCACAAAA AGTAAAGC-3' (SEQ ID NO: 4) 5'-TCGAGCTTTACTTTTTGTGGAACAGCTGGATCAGCCAACCCACTTT CGGTG-3NSEQ ID NO: 5) Sixteen μg of each oligonucleotide were annealed in a 50 μL reaction in 100 mM NaCl, 10 mM Tris, pH 7.8, 1 mM EDTA for 10 minutes at 68°C, 30 minutes at 57°C, and followed by slow cooling to room temperature. The resulting annealed oligonucleotide fragment encodes an Asp-Pro -Pro sequence followed by sequence encoding a peptide with the 12 amino acid sequence of XMP.391, as described in U.S. Patent No. 5,851,802: Asp Pro Pro Lys Val Gly Tip Leu He Gin Leu Phe His Lys Lys (SEQ ID NO: 6) The annealed oligonucleotide fragment also contains restriction enzyme sites for cleavage by BamRl at the 5' end and Xhol at the 3' end of sequence. The resulting annealed oligonucleotide was purified by centrifugation on a Chroma Spin 10 column (Clontech, Palo Alto, CA). Second, DNA fragments from two plasmid vectors were prepared. Plasmid pIClOO, a derivative of pBR322 and which includes the leader sequence of the E. carotovora pelB gene, described in U.S. Patent No. 5,416,202 (see, e.g., Example 10) incorporated by reference, was digested with EeoRI and Xhol, and the large vector fragment of approximately 2836 bp, was purified. Plasmid pING3353, described in U.S. Patent No. 5,851,802, incorporated by reference, was digested with EeoRI and BamHl and the approximately 550 bp fragment which encodes the pelB:Bone D protein was purified. Third, the annealed oligonucleotide, the EeoRI to Xhol fragment from pINGlOO and the EeoRI to BamHl fragment from pING3353 were ligated in 20 μL 50 mM Tris, pH 7.6, 10 mM MgCl 2 , 1 mM ATP, 1 mM DTT, 5% PΕG-8000 with 3 Units T4 DNA Ligase for 16 hours at 4C° to generate the intermediate vector pING4700. Plasmid pING4700 confers ampicillin resistance and encodes the fusion protein Bone D-Asp-Pro-peptide. Plasmid pING4700 was digested with EeoRI and Xhol, and the 604 bp fragment encoding the fusion protein was ligated to the approximately 5500 bp vector fragment from pING3217, as described in U.S. Patent 5,851,802, (see Example 1), that had been digested with EeoRI and Xhol in μL 50 mM Tris, pH 7.6, 10 mM MgCl 2 , 1 mM ATP, 1 mM DTT, 5% PΕG-8000 with 3 Units T4 DNA Ligase for 16 hours at 4C°. The resulting plasmid, pING4702, encodes the Bone D-Asp-Pro-Pro-peptide fusion protein (SΕQ ID NOS: 7 and 8) under the transcriptional control of the araB promoter. Plasmid pING4702 confers resistance to the antibiotic tetracycline. 2. Bacterial Expression Vector Construct pING4703 A second bacterial expression vector was constructed which encodes a peptide fusion protein containing Bone D (see, amino acid 23 through 161 of SEQ ID NOS: 1 and 2), the dipeptide Asp-Pro and a 25 amino acid peptide derived from the sequence of BPI (SEQ ID NO: 9). This vector construct, pING4703, was prepared as described below. First, two synthetic ohgonucleotides were synthesized that encode a BPI- derived peptide, an Asp-Pro-Pro sequence and appropriate restriction enzyme recognition sites for cloning. The ohgonucleotides encoding this sequence were: 5'- CATTGGATCCACCGAAATGGAAGGCCCAGTTTCGCTTTCTTAA GAAA TCGAAAGTGGGTTG -3' (SEQ ID NO: 10) 5 ' - GGCTCTCGAGCTCTACTTTTTATGAAACAGCAGGATCAGCCAACC CACTTTCGATTTCTTA -3 ' (SEQ ID NO: 1 1) Sixteen μg of each oligonucleotide were annealed in a 50 μL reaction in 100 mM NaCl, 10 mM Tris, pH 7.8, 1 mM EDTA for 10 minutes at 68°C, 30 minutes at 57°C, followed by slow cooling to room temperature. An aliquot of the annealed ohgonucleotides was diluted into 10 mM Tris, pH 8.3, 50 mM KC1 (300 μL total volume) and filled-in with a reaction containing AmpliTaq (Perkin Elmer, Norwalk, CT), dATP, dGTP, dCTP and dTTP at 72°C. The resulting double-stranded fragment encoded the restriction sites BamHl and Xhol at the 5' and 3 ' ends, respectively, and encoded an Asp-Pro-Pro sequence followed by a sequence encoding a peptide with the 24 amino sequence of XMP.102, as described in U.S. Patent No. 5,851,802: Asp Pro Pro Lys Tip Lys Ala Gin Phe Arg Phe Leu Lys Lys Ser Lys Val Gly Tip Leu He Leu Leu Phe His Lys Lys (SEQ ID NO: 12) The double-stranded fragment was digested with BamHl and Xhol, and ligated to both the approximately 5500 bp EeoRI toNbol vector fragment from pING3217, and the approximately 550 bp EeoRI to BamHl fragment of pING3353 in 20 μL 50 mM Tris, pH 7.6, 10 mM MgCl 2 , 1 mM ATP, 1 mM dithiothreitol, 5% PΕG-8000 with 1 Unit T4 DNA Ligase for 16 hours at 4C°. The resulting plasmid, pING4703, encodes the Bone D-Asp-Pro-Pro-peptide fusion protein (SEQ ID NOS: 13 and 14) under the transcriptional control of the araB promoter. Plasmid pING4703 confers resistance to the antibiotic tetracycline. EXAMPLE 2 Expression of Recombinant Fusion Proteins Expression of a recombinant product under control of the araB promoter was evaluated as follows. Expression vector constructs were transformed into E. coli E104 (deposited as ATCC 69009; ATCC 69008; ATCC 69101; ATCC 69102; ATCC 69103; ATCC 69104; ATCC 69331 ; ATCC 69332; ATCC 69333, each containing a gelonin-encoding plasmid) and tetracycline resistant colonies were selected. Bacterial cultures from these colonies were grown at 37°C in TYE medium (15 g Tryptone, 10 g Yeast Extract, 5 g NaCl per liter) supplemented with 15 μg/mL of tetracycline. For storage of bacterial cells prior to growth in a fermentor, bacterial cultures (1 to 2 mL) were frozen in TYE medium supplemented with 15% glycerol and stored at -20°C. To initiate production of recombinant product, a vial of cells containing the product expression vector was thawed, and inoculated into 100 mL of GMM culture medium as described below and grown to approximately 200 Klett Units, then inoculated into either a 14 L or 35 L fermentor. Each fermentor contained a minimal salts medium with glycerol as a carbon source (Glycerol Minimal Medium, GMM). The 14 L or 35 L fermentor vessel initially contained approximately 7 L or 20 L, respectively, of GMM which contains the following ingredients per liter: Autoclaved Ingredients (NH 4 ) 2 SO 4 12 g KH 2 PO 4 1 -57 g K 2 HPO 4 14.1 g MgSO 4 .7H 2 O 0.28 g H 3 PO 4 (Cone.) 3 mL Antifoam 1 mL Biotin 0.0012 g Yeast Extract 4.6 g Glycerol 18.5 g Filter sterilized ingredients CaCl 2 .2H 2 O ( 10% w/v) 1 mL Trace D Solution* 16 mL Thiamine HC1 (10% w/v) 0.1 mL Nicotinic Acid (1% w/v) 2 mL * Trace D solution is composed of: FeCl 3 .6H 2 O 6.480 g ZnSO 4 .7H 2 0 1.680 g MnCl 2 .4H 2 0 1.200 g Na 2 MoO 4 .2H 2 O 0.576 g CuSO 4 .5H 2 O 0.240 g CoCl 2 .6H,O 0.240 g H3BO3 0.720 g H 3 PO 4 (Cone.) 96.0 mL H 2 O (Batch Volume) 2.0 L The fermentor was then inoculated with the bacterial seed culture, and was maintained at pH 6.0 and 32°C with 10 L/min. air and agitation at 1000 rpm. When nutrients became limiting (as judged by an increase in the dissolved oxygen, DO, to approximately 100%), the culture was fed with additional nutrients until the culture reached an optical density (OD oo) of approximately 100. Culture feed rate was controlled to maintain the DO to a setpoint of 20%. Specifically, the culture was fed with the first feed: Autoclaved ingredients per liter of feed: Glycerol 700 g MgSO 4 .7H 2 O 10 g Biotin 0.01 g Filtered ingredients per liter of feed CaCl 2 .2H 2 O (10% w/v) 35 mL Thiamine HC1 ( 10% w/v) 3.5 mL Nicotinic Acid (1 % w/v) 7 mL The culture was induced by gradient induction at an OD of approximately 100 with a second feed containing the inducing agent L-arabinose. Specifically, the second feed was: Autoclaved ingredients per liter of feed: Glycerol 700 g MgSO 4 .7H 2 O 10 g Biotin 0.01 g Arabinose 60 g/L Filtered ingredients per liter of feed CaCl 2 .2H 2 O (10% w/v) 35 mL Thiamine HC1 (10% w/v) 3.5 mL Nicotinic Acid (1% w/v) 7 mL The cultures were harvested 23-26 hours post induction. The cells may be separated from the culture medium with a 0.2 μm hollow fiber cartridge, 10 ft. (Microgon, Laguna Hills, CA) as described in Examples 3 and 5 below. Alternatively, the fermentation broth (i.e., culture medium with cells) may be used directly in the fermentation vessel or removed from the fermentor for acidification and further processing as described in Examples 4 and 5 below. Example 6 below describes the recovery and purification of recombinant peptides. EXAMPLE 3 Acid Hydrolysis of Bacterial Cells and Release of Recombinant Peptide 1. Peptide release from bacterial cells Previously, inclusion bodies were isolated. Acid treatment of the isolated inclusion bodies resulted in the hydrolysis of the aspartyl-prolyl bond (Asp-Pro) between the Bone D protein and a recombinant peptide by incubation in dilute acid at elevated temperatures (see, e.g. Example 3 of U.S. Patent No. 5,851,802). In these experiments, bacterial cells were directly acidified in an attempt to lyse the cells and hydrolyze the inclusion bodies directly to release the peptide. This was done by diluting cells in dilute acid at elevated temperature. E. coli El 04 containing plasmid pING4702 was grown in a 10 L fermentor and induced with arabinose. After termination of the fermentor run, bacterial cells were separated from the majority of the culture supernatant with a 0.2 μm hollow fiber cartridge (Microgon ,10ft ) and frozen. Cells obtained from the fermentor were thawed and incubated under acidic conditions for 4 hours at 85°C as follows in Table 1. TABLE 1 As a control, approximately 1 gram of cells were lysed with lysozyme and inclusion bodies were isolated prior to acid hydrolysis according to prior methods (see, e.g., Example 3 of U.S. Patent No. 5,851,802). These cells were suspended in 10 mL of 100 mM Tris, 5 mM EDTA, pH 8.0. The slurry was incubated on ice for 15 minutes, and 1 mL of 10 mg/mL lysozyme was added and incubated on ice for 20 minutes. To disrupt the lysozyme treated cells, the slurry was sonicated 4 times for 10 seconds each at the highest setting using a Sonic U sonicator (B. Braun Biotech Inc., Allentown, PA). The lysed cells were centrifuged at 13,000 rpm in a JA20 rotor for 25 minutes. The inclusion body pellet was then incubated in 10 mL of 30 mM HC1 for 4 hours at 85°C. Prior to incubation at 85°C, the pH of all samples was adjusted to pH 2.5 with HC1, except for the sample containing urea which was adjusted to pH 3.0. After incubation, the samples were centrifuged at 13,000 rpm in a JA20 rotor for 25 minutes to separate soluble from insoluble material. The amount of released peptide in the supernatant from each sample was evaluated by HPLC using a Beckman Coulter (Fullerton, CA) instrument with a Shimadzu Scientific Instruments (Columbia, MD) auto injector and a Vydac (Hesperia, CA) C18 (#218TP54) column. Solvent A was 10% acetonitrile/0!% TFA; solvent B was 90%) acetonitrile/0.1%) TFA. The column was run with an 20-40%) B gradient over 20 minutes at a flow rate of 1 mL/minute with peptide detection at 229 nm. The concentration of peptide in the supernatant was as follows in Table 2. TABLE 2 These data demonstrate for the first time that peptide could be released directly from cells by incubation of the bacterial cells in dilute acid while the majority of other proteins remain insoluble. 2. Timecourse of peptide release from bacterial cells. The results described above demonstrated that peptide was released from a Bone D-peptide fusion protein containing an acid sensitive Asp-Pro peptide linker by direct hydrolysis of cells in dilute acid. Studies were performed to examine the timecourse for hydrolysis. A sample of the same concentrated, frozen cell sample described above was used for additional studies. Approximately 2 grams of cell paste was diluted with 20 mL of water and concentrated HC1 was added to bring the pH to 2.5. The sample was incubated at 85°C, and samples were removed periodically for quantitation. Each sample was centrifuged to remove insoluble material, and the supernatant was assayed for released peptide by HPLC. The concentration of peptide in the soluble fraction was as follows in Table 3. TABLE 3 Thus, as shown in Table 3, the amount of peptide in the soluble fraction was still increasing at the end of the seven hour timecourse. In additional studies, a cell sample of bacterial cells in cell culture media was incubated at pH 2.15 to evaluate the timecourse of peptide release from cells that had not been previously concentrated and frozen. Specifically, 40 mL of bacterial cells in fermentation broth (fermentation culture of E. coli El 04 containing pING4702) at the end of the fermentor process as described in Example 2 was directly adjusted to pH 2.15 by adding 500 μL of concentrated HC1, to a final concentration of approximately 150 mM. The sample was incubated at 85°C and every hour a sample was removed, centrifuged, and the supernatant was evaluated for peptide by HPLC. The amount of peptide released over time was as follows in Table 4. TABLE 4 At pH 2.15 and using cells directly in the fermentation medium, maximum release of peptide occurred by seven hours at 85°C, after which the amount of released peptide decreased. Additional studies demonstrated that dilute H SO 4 and HNO 3 could also release soluble peptide from bacterial cells and bacterial cells in cell culture media (i.e., fermentation cultures). In studies with H SO 4 , two 20 mL samples of bacterial cells in fermentation broth as described in Example 4 (fermentation culture of E. coli El 04 containing pING4702) were collected after completion of a bacterial fermentation, and they were acidified to pH 2.4. One sample was adjusted to pH 2.4 with HC1 and the other was adjusted to pH 2.4 with H 2 SO 4 . Each sample was incubated at 85°C, a sample was removed every hour for seven hours and the amount of soluble peptide in each sample was analyzed by HPLC. The concentration of peptide in each aliquot is shown in the following Table 5. TABLE 5 In studies with HNO 3 , a sample of cells in bacterial fermentation broth as described in Example 4 was incubated with nitric acid. Specifically, 20 mL of cells were adjusted to pH 2.2 with nitric acid and incubated at 85°C. Samples were removed periodically and the concentration of recombinant peptide in the soluble fraction was determined by HPLC. The concentration of peptide in each aliquot is shown in the following Table 6. TABLE 6 These additional studies demonstrate that acids such as nitric acid, that are less corrosive to stainless steel materials used in fermentation vessels, are useful in the improved methods of the invention. EXAMPLE 4 Acid Hydrolysis of Bacteria Directly in a Fermentation Vessel Since peptide was released from bacterial cells and cell cultures by direct incubation of cells in acid as described in Example 3, studies were done to evaluate if soluble peptide could be recovered directly from a bioreactor at the end of the fermentation process when contents of the fermentor were acidified and heated in place. In initial studies, E. coli El 04 containing pING4702 was grown in a 35 L fermentor as described in Example 2. The first feed solution was introduced in the fermentor at 20.5 hours after inoculation, and the culture was induced with the second feed when the OD600 had reached 97.2. At 62.5 hours after induction, 10%> HC1 was added to the fermentor in 50 mL aliquots until the pH of the fermentor had reached approximately 2.28. In total, 990 mL of acid was added to the approximately 26 L of fermentation product in the fermentor. After reducing the pH, the temperature setpoint on the fermentor was increased to 85°C, and samples were removed from the fermentor periodically thereafter for six hours. The contents of the vessel were mixed during the reaction with the fermentor impellers. HPLC analysis of the soluble material in the samples revealed that the concentration of the peptide leveled off between four and five hours. The concentration of peptide was as shown in the following Table 7. TABLE 7 In additional studies, E. coli El 04 containing pING4702 was grown in a 35 L fermentor to an OD600 of 89, induced with the second feed containing arabinose and grown for 24 hours. A 10%> HC1 solution was added to bring the culture pH to approximately 2.3, and the temperature was raised to 85°C for 5.5 hours. The concentration of peptide in the soluble fraction was 0.332 mg/mL. EXAMPLE 5 Acid Hydrolysis of Bacteria After Removal of the Cell Culture Medium E. coli El 04 containing pING4703 was grown in a 14 L fermentor as described in Example 2, and 10 mL of the fermentation culture was adjusted to pH 2.2 with concentrated HCl. The sample was incubated at 85°C, and samples were taken every few hours and analyzed for peptide in the supernatant by HPLC, using the same method as described in Example 3 for quantitation of peptide from the product encoded by pING4702. The results from this study are shown in the following Table 8. TABLE 8 These peptide titers were much lower than what was obtained with cultures of E. coli El 04 (pING4702) as described in Examples 3 and 4, and lower than the titer obtained when E. coli El 04 (pING4703) was lysed by sonication after incubation with lysozyme by the process described in Example 3. E. coli El 04 (pING4703) lysed by sonication after lysozyme treatment had a titer of approximately 0.46 mg/mL in the soluble fraction. In additional studies, samples of the bacterial cell culture both before and after acid hydrolysis at 85°C were analyzed by SDS-PAGE. The results demonstrated that the fusion protein of Bone D and peptide had been hydro lyzed by acid. An experiment was executed to determine if the cell culture medium in the hydrolysis reaction had an impact on the ability to recover recombinant peptide in the soluble fraction, since a prominent band at the position of Bone D was apparent in the hydrolyzed sample, while very little intact fusion protein was detected. Cell paste from the fermentation of E. coli El 04 (pING4703) was prepared by centrifugation, and 1 g of cell paste was suspended in: 7 mL H2O; 7 mL of 5 mM EDTA; or 7 mL of cell-free fermentation broth from the same bacterial fermentor. Each sample was adjusted to pH 2.2 with concentrated HCl, and incubated at 85°C. The amount of recombinant peptide in the soluble fraction was measured over time by HPLC. The results are shown in the following Table 9. TABLE 9 These data demonstrated that the recombinant peptide was soluble when the cells were hydrolyzed in water or 5 mM EDTA, but did not become soluble in the fermentation medium after acid hydrolysis. Further studies were performed to determine if recombinant peptide was insoluble in acid after hydrolysis from Bone D, and could be released from the insoluble material in detergents or chaotropic salts. Three 1 gram samples of cell paste from E. coli El 04 (pING4703) were suspended in 7 mL of 100 mM Tris, 5 mM EDTA, pH 8.0, and one 1 gram sample of cell paste was suspended in 7 mL of cell-free culture medium from the E. coli fermentation. To one of the samples suspended in Tris buffer, 1 mL of 10 mg/mL lysozyme was added, the sample was incubated on ice and sonicated as described in Example 3. The pH of all four samples was adjusted to approximately pH 2.0 with concentrated HCl, and the samples were incubated at 85°C for 4 hours. By HPLC, the amount of peptide released into the soluble fraction from the four samples was as follows in Table 10. TABLE 10 Thus, peptide did not appear in the soluble fraction in Sample 3 after acid hydrolysis. To determine if peptide could be released from the insoluble material, the pellet from Sample 3 was washed sequentially with 7 mL of buffer containing Triton X-100, urea, guanidine hydrochloride or SDS. The amount of peptide released from the pellet was as follows in Table 11. TABLE 11 These results demonstrated that the peptide could be recovered from the insoluble material by washing in buffers containing urea or guanidine hydrochloride. The peptide was therefore not degraded by the hydrolysis condition, but is rendered insoluble by media components. The total amount of material recoverable in all washes was 2.67 mg per gram of cells, compared to 4.16 mg/g and 3.63 mg/g recovered directly from the soluble material in Samples 1 and 4 , respectively. Thus, for some bacterial cell cultures, the bacterial cells may be preferentially removed from the media and the bacterial cells may be acidified according to Example 3. For other bacterial cell cultures, the fermentation broth (bacterial cells in cell culture/fermentation media) may be directly acidified according to Examples 3 and 4. EXAMPLE 6 Recovery and Purification of Recombinant Peptide from Acid Hydrolyzed Cells 1. Recovery The invention provides methods for the recovery of peptides in the soluble fraction after acid hydrolysis of cells while the large majority of other bacterial proteins, the carrier protein, and other impurities remain in the insoluble fraction. The soluble and insoluble material can be separated by centrifugation, filtration or any other suitable separation method. Any variety of centrifuge can be used to separate these materials and a variety of filtration devices, systems and methods can also be used. A variety of such filtration devices, systems and methods were used to separate soluble and insoluble materials including dead end (depth) filtration and tangential flow filtration. A summary of the results of exemplary filtration studies to separate soluble and insoluble material by filtration is presented in the following Table 12. TABLE 12 ND - not determined Seitz filters are products of SWK Filtration Incorporated, Petaluma, CA. Cuno filters are products of Cuno, Meriden, CT. Celite is a product of World Minerals, Lompoc, CA. Sartorius filters are products of Sartorius, Edgewood, NY. These results demonstrate that a variety of filtration devices, systems and methods can be successfully employed to separate the soluble and insoluble material. 2. Purification Following fermentation of E. coli El 04 containing pING4702 as described in Example 2, bacterial cells in the unprocessed fermentation broth were hydrolyzed in dilute HCl. Specifically, 40 mL of fermentation broth was adjusted to pH 2.15 with concentrated HCl. The sample was incubated at 85°C for 5.5 hours. The hydrolyzed cells were then centrifuged to remove insoluble material, and the supernatant was adjusted to pH 3.0 by adding 500 mM sodium citrate drop wise. An SP Sepharose (Amersham-Pharmacia, Piscataway, NJ) column, 2.5 x 4.4 cm containing 21.6 mL, was equilibrated in 10 mM sodium citrate, pH 3.0 and the sample was loaded. The column was washed with 10 mM sodium citrate , pH 3.0 buffer and then 10 mM sodium phosphate, pH 7.0 until the pH of the column effluent reached 7. The column was then washed in 10 mM sodium phosphate, 150 mM NaCl pH 7.0. The column was eluted in 10 mM sodium phosphate, 800 mM NaCl pH 7.0 and then the column was stripped with 10 mM sodium phosphate, 2 M NaCl. The SP Sepharose eluate was diluted with one volume of 10 mM sodium phosphate, 3 M ammonium sulfate, pH 7.0. A Butyl Sepharose (Amersham-Pharmacia) column, 1 x 4 cm containing 3.1 mL, was equilibrated with 10 mM sodium phosphate, 1.5 M ammonium sulfate, pH 7.0, and the sample was loaded. The Butyl Sepharose column was washed with 10 mM sodium phosphate, 1.1 M ammonium sulfate, pH 7.0, and then eluted with 10 mM sodium phosphate, 0.4 M ammonium sulfate, pH 7.0. The column was striped with 10 mM sodium phosphate, pH 7.0 The peptide concentration in each of the fractions from the SP Sepharose and Butyl Sepharose columns was followed by HPLC analysis. The sample volumes, peptide concentrations and percent recovery was as follows in Table 13. TABLE 13 ND -Not Determined A Superdex 30 (Amersham-Pharmacia) column, 1.6 x 53 cm containing 107 mL, was equilibrated in 5 mM sodium acetate, 150 mM NaCl, pH 5.0. Eight mL of Butyl Seph«arose eluate was loaded onto the Superdex 30 gel filtration column, and the column was run with 5 mM sodium acetate, 150 mM NaCl, pH 5.0. After 32 mL had flowed through the column, 3 mL fractions were collected. Fractions 12-19 were pooled and had a volume of approximately 20 mL. The concentration of recombinant peptide in the Superdex 30 pool was 0.107 mg/mL for a recovery of 102% from the previous step, and the overall recovery from the acid hydrolysate of cells was 76.6%. The final peptide purity was 91.4%. EXAMPLE 7 Biological Activity Assays of Recombinant Peptides A variety of recombinant peptides, including those BPI-derived peptides comprising the sequences listed in U.S. Patent No. 5,851,802 incorporated by reference, may be produced by recombinant methods of the invention and tested for biological activity by known activity assays. Assays for antimicrobial activity (both anti-fungal and anti-bacterial activity) may be performed, including radial diffusion assays. Assays, with a variety of fungal and bacterial cells, including those described in U.S. Patent No. 5,851,802 (see Example 6), may be conducted using recombinant peptides produced according to the invention. For example, studies were performed to evaluate the antifungal activity of the recombinant peptide from pING4702 purified according to Example 6 in a broth microdilution assay using four strains of C. albicans, C glabrata and S cerevisiae. A similar peptide, XMP.391, that was chemically synthesized, was included in the assay as a positive control. To perform the broth microdilution assay, the fungal cultures were grown overnight at 30°C in YPD medium (1%> yeast extract, 2%> peptone, and 2%> dextrose). A 400 fold dilution of each culture in YPD was then made, and grown at 30°C for 8 hours. Three mL of each culture were collected by centrifugation and suspended in 0.9%> NaCl to an A600 of about 0.3. These cultures were further diluted to 1 x 10 4 CFU/mL in Sabouraud dextrose broth (6 mL). Recombinant peptide was in 5 mM acetate, 150 mM NaCl, pH 5.0 at a concentration of about 2 mg/mL. Synthetic peptide was at about 1 mg/mL. Samples were serially diluted and added to microtiter plates containing the cultures. Plates were incubated at 30°C for 48 hours before growth inhibition was measured. Results from this assay were as follows in Table 14. TABLE 14 Additionally or alternatively, assays may be performed to assess the endotoxin binding and neutralizing activity of the recombinantly produced peptides, by a variety of known assays, including those described in co-owned U.S. Patent Nos. 5,733,872 and 5,763,567 [WO 94/20532 (PCT/US94/02465)]; 5,652,332 and 5,856,438 [WO 95/19372 (PCT/US94/10427)]; 5,858,974 [WO 96/08509 (PCT/US95/09262) and WO 97/04008 (PCT/US96/03845)]; incorporated by reference in their entirety. Additionally or alternatively, assays may be performed to assess the heparin binding and neutralizing activity of the recombinantly produced peptides by a variety of known assays, including assays as described in U.S. Patent Nos. 5,348,942; 5,639,727; 5,807,818; 5,837,678; and 5,854,214 [WO 94/20128 (PCT/US94/02401)]; 5,733,872 and 5,763,567 [WO 94/20532 (PCT/US94/ 02465)]; 5,652,332 and 5,856,438 [WO 95/19372 (PCT/US94/10427)]; incorporated by reference in their entirety. It should be understood that the foregoing disclosure emphasizes certain specific embodiments of the invention and all modifications or alternatives equivalent thereto are within the spirit and scope of the invention as set forth in the appended claims. In particular, numerous modifications and variations in the practice of the invention are expected to occur to those skilled in the art upon consideration of the foregoing description on the presently preferred embodiments thereof. Consequently, the only limitations which should be placed upon the scope of the present invention are those that appear in the appended claims.

Claims: WHAT IS CLAIMED IS: 1. In a method for obtaining a peptide from bacterial cells after expression inside the cells of a fusion protein, wherein the fusion protein comprises the peptide, a carrier protein and an acid-cleavable site between the peptide and the carrier protein, the improvement comprising: treating the bacterial cells with acid under conditions sufficient in a single step to disrupt or lyse the cells and release the peptide from the fusion protein. 2. The method of claim 1 with the additional step of obtaining the released peptide separated from the disrupted or lysed cells. 3. The method of claim 2 wherein the released peptide is separated from the disrupted or lysed cells by a separation device. 4. The method of claim 3 wherein the separation device is a centrifugation device. 5. The method of claim 3 wherein the separation device is a filtration device. 6. The method of claim 1 wherein the acid-cleavable site in the fusion protein is Asp-Pro. 7. The method of claim 1 wherein the carrier protein is expressed as an insoluble protein inside the bacterial cells. 8. The method of claim 7 wherein the carrier protein is the D subunit of human osteogenic protein. 9. The method of claim 1 wherein the bacterial cells are in cell culture media for the acid treatment. 10. The method of claim 1 wherein the bacterial cells have been separated from cell culture media for the acid treatment. 11. The method of claim 1 wherein the bacterial cells are in cell culture media in a fermentation vessel for the acid treatment. 12. In a method for obtaining a peptide from bacterial cells after expression inside the cells of a fusion protein, wherein the fusion protein comprises the peptide, a carrier protein and an acid-cleavable site between the peptide and the carrier protein, the improvement comprising: (a) treating the bacterial cells with acid under conditions sufficient to disrupt or lyse the cells and release the peptide from the fusion protein, (b) separating soluble material from insoluble material after step (a), and (c) recovering the released peptide in the soluble material after step (b). 13. The method of claim 12 wherein the soluble material is separated from the insoluble material by a separation device. 14. The method of claim 13 wherein the separation device is a centrifugation device. 15. The method of claim 13 wherein the separation device is a filtration device. 16. The method of claim 12 wherein the acid-cleavable site in the fusion protein is Asp-Pro. 17. The method fo claim 12 wherein the carrier protein is expressed as an insoluble protein inside the bacterial cells. 18. The method of claim 17 wherein the carrier protein is the D subunit of human osteogenic protein. 19. The method of claim 12 wherein the bacterial cells are in cell culture media for the acid treatment. 20. The method of claim 12 wherein the bacterial cells have been separated from cell culture media for the acid treatment. 21. The method of claim 12 wherein the bacterial cells are in cell culture media in a fermentation vessel for the acid treatment.

Inventors: BETTER MARC D, GAVIT PATRICK D, BETTER, MARC, D., GAVIT, PATRICK, D.
Applicants: BETTER MARC D, GAVIT PATRICK D, XOMA TECHNOLOGY LTD, BETTER, MARC, D., GAVIT, PATRICK, D., XOMA TECHNOLOGY LTD.
Application year: 2000
Main classification: C12N15
IPC codes: C07K1, C07K14, C12N15, C12P21